Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
18
BMXXY Quote, Financials, Valuation and Earnings
Last price:
$12.43
Seasonality move
:
0%
Day range:
$12.43 - $12.43
52-week range:
$9.51 - $14.62
Dividend yield:
0.79%
P/E ratio:
36.00x
P/S ratio:
3.30x
P/B ratio:
3.94x
Volume:
5K
Avg. volume:
215
1-year change:
30.7%
Market cap:
$14.7B
Revenue:
$4.3B
EPS (TTM):
$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMXXY
bioMérieux SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -80.11% | $40.03 |
|
IPHA
Innate Pharma SA
|
$2.3M | -- | -- | -- | $5.15 |
|
IVA
Inventiva SA
|
$10.1M | -$0.27 | -- | -- | $15.33 |
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $14.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMXXY
bioMérieux SA
|
$12.43 | -- | $14.7B | 36.00x | $0.10 | 0.79% | 3.30x |
|
CLLS
Cellectis SA
|
$4.96 | $7.20 | $497.6M | -- | $0.00 | 0% | 6.17x |
|
DBVT
DBV Technologies SA
|
$19.52 | $40.03 | $534.1M | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.70 | $5.15 | $156.7M | -- | $0.00 | 0% | 21.95x |
|
IVA
Inventiva SA
|
$4.55 | $15.33 | $663.7M | -- | $0.00 | 0% | 26.49x |
|
NBTX
Nanobiotix SA
|
$22.49 | $14.75 | $1.1B | -- | $0.00 | 0% | 31.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMXXY
bioMérieux SA
|
7.04% | 1.602 | -- | 1.22x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
IPHA
Innate Pharma SA
|
55.22% | -1.046 | -- | 2.76x |
|
IVA
Inventiva SA
|
-145.15% | -0.179 | 32.05% | 0.43x |
|
NBTX
Nanobiotix SA
|
195.9% | 4.777 | 20.12% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMXXY
bioMérieux SA
|
-- | -- | 10.03% | 10.95% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
bioMérieux SA vs. Competitors
-
Which has Higher Returns BMXXY or CLLS?
Cellectis SA has a net margin of -- compared to bioMérieux SA's net margin of 1.68%. bioMérieux SA's return on equity of 10.95% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital BMXXYbioMérieux SA-- -- $4.7B CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About BMXXY or CLLS?
bioMérieux SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 45.16%. Given that Cellectis SA has higher upside potential than bioMérieux SA, analysts believe Cellectis SA is more attractive than bioMérieux SA.
Company Buy Ratings Hold Ratings Sell Ratings BMXXYbioMérieux SA0 0 0 CLLSCellectis SA2 2 0 -
Is BMXXY or CLLS More Risky?
bioMérieux SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
-
Which is a Better Dividend Stock BMXXY or CLLS?
bioMérieux SA has a quarterly dividend of $0.10 per share corresponding to a yield of 0.79%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioMérieux SA pays 14.48% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. bioMérieux SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMXXY or CLLS?
bioMérieux SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. bioMérieux SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, bioMérieux SA's price-to-earnings ratio is 36.00x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioMérieux SA is 3.30x versus 6.17x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMXXYbioMérieux SA3.30x 36.00x -- -- CLLSCellectis SA6.17x -- $35M $586.4K
-
Which has Higher Returns BMXXY or DBVT?
DBV Technologies SA has a net margin of -- compared to bioMérieux SA's net margin of --. bioMérieux SA's return on equity of 10.95% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital BMXXYbioMérieux SA-- -- $4.7B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About BMXXY or DBVT?
bioMérieux SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 104.13%. Given that DBV Technologies SA has higher upside potential than bioMérieux SA, analysts believe DBV Technologies SA is more attractive than bioMérieux SA.
Company Buy Ratings Hold Ratings Sell Ratings BMXXYbioMérieux SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is BMXXY or DBVT More Risky?
bioMérieux SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock BMXXY or DBVT?
bioMérieux SA has a quarterly dividend of $0.10 per share corresponding to a yield of 0.79%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioMérieux SA pays 14.48% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. bioMérieux SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMXXY or DBVT?
bioMérieux SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. bioMérieux SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, bioMérieux SA's price-to-earnings ratio is 36.00x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioMérieux SA is 3.30x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMXXYbioMérieux SA3.30x 36.00x -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns BMXXY or IPHA?
Innate Pharma SA has a net margin of -- compared to bioMérieux SA's net margin of --. bioMérieux SA's return on equity of 10.95% beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital BMXXYbioMérieux SA-- -- $4.7B IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About BMXXY or IPHA?
bioMérieux SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 203.18%. Given that Innate Pharma SA has higher upside potential than bioMérieux SA, analysts believe Innate Pharma SA is more attractive than bioMérieux SA.
Company Buy Ratings Hold Ratings Sell Ratings BMXXYbioMérieux SA0 0 0 IPHAInnate Pharma SA3 2 0 -
Is BMXXY or IPHA More Risky?
bioMérieux SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.
-
Which is a Better Dividend Stock BMXXY or IPHA?
bioMérieux SA has a quarterly dividend of $0.10 per share corresponding to a yield of 0.79%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioMérieux SA pays 14.48% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. bioMérieux SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMXXY or IPHA?
bioMérieux SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. bioMérieux SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, bioMérieux SA's price-to-earnings ratio is 36.00x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioMérieux SA is 3.30x versus 21.95x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMXXYbioMérieux SA3.30x 36.00x -- -- IPHAInnate Pharma SA21.95x -- -- --
-
Which has Higher Returns BMXXY or IVA?
Inventiva SA has a net margin of -- compared to bioMérieux SA's net margin of --. bioMérieux SA's return on equity of 10.95% beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMXXYbioMérieux SA-- -- $4.7B IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About BMXXY or IVA?
bioMérieux SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 237%. Given that Inventiva SA has higher upside potential than bioMérieux SA, analysts believe Inventiva SA is more attractive than bioMérieux SA.
Company Buy Ratings Hold Ratings Sell Ratings BMXXYbioMérieux SA0 0 0 IVAInventiva SA8 0 0 -
Is BMXXY or IVA More Risky?
bioMérieux SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.
-
Which is a Better Dividend Stock BMXXY or IVA?
bioMérieux SA has a quarterly dividend of $0.10 per share corresponding to a yield of 0.79%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioMérieux SA pays 14.48% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. bioMérieux SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMXXY or IVA?
bioMérieux SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. bioMérieux SA's net income of -- is lower than Inventiva SA's net income of --. Notably, bioMérieux SA's price-to-earnings ratio is 36.00x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioMérieux SA is 3.30x versus 26.49x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMXXYbioMérieux SA3.30x 36.00x -- -- IVAInventiva SA26.49x -- -- --
-
Which has Higher Returns BMXXY or NBTX?
Nanobiotix SA has a net margin of -- compared to bioMérieux SA's net margin of --. bioMérieux SA's return on equity of 10.95% beat Nanobiotix SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMXXYbioMérieux SA-- -- $4.7B NBTXNanobiotix SA-- -- $24.3M -
What do Analysts Say About BMXXY or NBTX?
bioMérieux SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -30.24%. Given that Nanobiotix SA has higher upside potential than bioMérieux SA, analysts believe Nanobiotix SA is more attractive than bioMérieux SA.
Company Buy Ratings Hold Ratings Sell Ratings BMXXYbioMérieux SA0 0 0 NBTXNanobiotix SA4 1 0 -
Is BMXXY or NBTX More Risky?
bioMérieux SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMXXY or NBTX?
bioMérieux SA has a quarterly dividend of $0.10 per share corresponding to a yield of 0.79%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. bioMérieux SA pays 14.48% of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend. bioMérieux SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMXXY or NBTX?
bioMérieux SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. bioMérieux SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, bioMérieux SA's price-to-earnings ratio is 36.00x while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for bioMérieux SA is 3.30x versus 31.37x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMXXYbioMérieux SA3.30x 36.00x -- -- NBTXNanobiotix SA31.37x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
